FDA 2026 Container Closure Draft: Device-Constituent CCS, 510(k), & October Clock

FDA August 2026 container closure systems draft guidance: device-constituent CCS vs packaging, 510(k)/PMA vs NDA, Section V.B.3, and Docket FDA-2026-D-7957.

For regulatory affairs directors, chemistry, manufacturing, and controls (CMC) leads, quality engineers, and device-constituent hardware suppliers developing prefilled syringes (PFS), autoinjectors, on-body delivery systems, pumps, metered-dose inhalers (MDIs), and intravenous (IV) infusion bags, the boundary between pharmaceutical packaging and medical device regulation has shifted into sharp focus.

In August 2026, the U.S. Food and Drug Administration (FDA) released a major 37-page draft guidance: Container Closure Systems for Human Drugs and Biological Products (Docket No. FDA-2026-D-7957; 91 FR 52700, August 14, 2026). The document was prepared by the Center for Drug Evaluation and Research (CDER) Office of Pharmaceutical Quality (OPQ) in cooperation with the Center for Biologics Evaluation and Research (CBER), the Center for Devices and Radiological Health (CDRH), the Office of Regulatory Affairs / Office of Inspections and Investigations (ORA/OII), and the Office of Combination Products (OCP).

Almost immediately, industry commentary created confusion. Some law-firm alerts asserted that the draft "supersedes" FDA's landmark May 1999 guidance. Gated trade newsletters announced that FDA had brought all combination-product device rules "under one roof." Meanwhile, search engines continue to return the May 1999 guidance as the leading authoritative source, while mixing in coverage of a separate biosimilar container closure draft issued around the same time.

Direct Answer. FDA's August 2026 document is a Draft Guidance — Not for Implementation. It is not a statute, not a final guidance, and not legally binding. It does not yet supersede the May 1999 guidance Container Closure Systems for Packaging Human Drugs and Biologics or the May 2002 Questions and Answers document. The draft itself says that when final, it will supersede those two documents. Until a final guidance is issued, keep the 1999 file as the still-published CCS guidance and treat the 2026 text as FDA's proposed thinking for comment and gap assessment of extractables and leachables (E&L), container closure integrity testing (CCIT), and device-constituent interfaces.

The draft applies to container closure systems (CCS) for human drugs and biological products, including CCS that are also device constituent parts of combination products (under 21 CFR 3.2(e) and 4.2), as well as CCS used to package drug or biologic constituent parts. Section III.C states that a CCS may also be a device constituent part if it has more than one function (for example, to be a container closure and to deliver the drug). Examples named there are piston syringes, pumps, metered dose inhalers (MDIs), and intravenous bags.

Footnote 11 defines "application" as INDs, NDAs, ANDAs, and BLAs, and also as IDEs, PMAs, De Novo requests, and 510(k)s for combination products covered by this guidance. Stand-alone devices are excluded from the stated scope; some recommendations may still be discussed with CDRH or CBER for a stand-alone device intended to deliver drugs. Section V.B.3 is the device-RA limit: a CCS that is also a device constituent remains subject to 21 CFR Part 4 CGMP and postmarketing safety reporting, and to premarket information supporting device performance, that are beyond the scope of this CMC guidance. ISO 13485:2016 Clause 7.3 (as required by 21 CFR 820.10(c)) and Clause 7.4 (as required by 21 CFR 820.10(a)) may overlap the CCS quality assessments after the Quality Management System Regulation (QMSR) effective date of 2 February 2026.

Comments on Docket FDA-2026-D-7957 submitted by October 13, 2026 are considered before FDA begins work on the final version; 21 CFR 10.115(g)(5) still lets you comment on any guidance at any time. There is no FDA user fee to comment. This docket is not Docket FDA-2026-D-4272 (the July 2026 biosimilar CCS and device-constituent draft; comments by October 2, 2026). Do not treat the 175,559 records in the July 22, 2026 public FDA 510(k) export as a combination-product CCS census: that snapshot's public descriptor has no combination-product or CCS field.

Status Dimension	Official Regulatory Reality (As of September 2026)	Operational Impact on Device-Constituent Sponsors
Document Status	August 2026 Draft Guidance; "Draft — Not for Implementation"; non-binding under 21 CFR 10.115	Keep 1999 guidance in active regulatory file; use 2026 draft for forward-looking gap assessments and comment strategy
May 1999 Supersession	Text states it will supersede May 1999 CCS guidance and May 2002 Q&A when final	1999 guidance remains published and current on FDA portal (as of May 6, 2020 listing); 1999 is not withdrawn
Docket & Notice	Docket No. FDA-2026-D-7957; published at 91 FR 52700 (August 14, 2026)	Public comment window open; comments due by October 13, 2026; 21 CFR 10.115(g)(5) allows comment at any time
Device-Constituent Scope	Covers CCS that also function as device constituent parts under 21 CFR 3.2(e) (contain and deliver)	Prefilled syringes, autoinjector prefilled cartridges/syringes, pumps, MDIs, and IV bags fall squarely into scope
Application Coverage	IND, NDA, ANDA, BLA, and for combination products: IDE, PMA, De Novo, and 510(k)	Applies across drug-led (CDER/CBER) and device-led (CDRH) combination-product marketing submissions
Exclusions from Scope	Stand-alone devices, secondary packaging operations, child-resistant packaging (16 CFR 1700)	Stand-alone drug-delivery devices consult CDRH/CBER; packaging operations stay under 21 CFR 211 / Part 4
Beyond-Scope Boundaries (V.B.3)	Part 4 CGMP, device performance, human factors, essential drug delivery outputs (EDDO), ISO 11608	CCS CMC data does not replace device DHF verification, usability validation, or clinical performance files
QMSR & Standards	Cites QMSR final rule (89 FR 7496, effective Feb 2, 2026); ISO 13485:2016 Clause 7.3 via 21 CFR 820.10(c) and Clause 7.4 via 21 CFR 820.10(a)	Design controls and supplier purchasing controls may overlap CCS suitability testing; they do not replace Part 4
Liquid Dispenser Trap	Footnote 82: 21 CFR 880.6430 QS exemption may not apply when a dropper is built into a bottle cap	Integrating an exempt dropper into a closure creates a combination CCS requiring design and quality controls
Companion Docket Split	Separate from Docket FDA-2026-D-4272 (Biosimilar and Interchangeable Biosimilar CCS/Device Draft)	Do not merge biosimilar comparative presentation analysis into standard CDER/CBER/CDRH CCS files
Fees & Master Files	No fee to comment; ordinary MDUFA/PDUFA application fees; Type III DMF and CDRH MAF recognized	Master file owners maintain confidentiality; device component files submit to CDRH MAF; drug/packaging to Type III DMF

Is the August 2026 CCS Draft Already Law, or a Nonbinding File That Does Not Yet Replace the May 1999 Guidance?

The first and most critical compliance error circulating in industry is the belief that FDA's August 2026 draft guidance is an enforceable regulation that instantly invalidated the agency's 1999 guidance. Several law-firm alerts inadvertently fueled this misconception by writing that "the new guidance supersedes the 1999 guidance."

It does not.

Under FDA's Good Guidance Practices regulation (21 CFR 10.115), guidance documents represent the agency's current thinking on a topic. They do not establish legally enforceable rights or responsibilities and do not bind FDA or the public. The August 2026 document is prominent in its designation:

The running header is stamped "Draft — Not for Implementation".
Lines 6–9: "This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public."
Lines 22–24: "When final, this guidance will supersede the guidances for industry Container Closure Systems for Packaging Human Drugs And Biologics (May 1999) and Container Closure Systems for Packaging Human Drugs and Biologics — Questions and Answers (May 2002)."

The words "When final" are decisive. The May 1999 guidance remains published, active, and indexed on FDA's official regulatory guidance database (listing content current as of May 6, 2020; Docket FDA-1997-D-0145). The 1999 guidance is what FDA reviewers have historically applied and what existing marketing authorizations rest upon.

Layer	Instrument	Operating status as of September 2026
Binding law	FD&C Act; 21 CFR 211.94 (drug containers); 21 CFR Part 4 (combination products); 21 CFR 820.10 (QMSR / ISO 13485:2016)	Still in force. The draft does not amend these sections.
Published final guidance	May 1999 CCS guidance and May 2002 Q&A	Still published on FDA's portal; still the active CCS listing
August 2026 draft	Docket FDA-2026-D-7957; comments considered through Oct 13, 2026	"Draft — Not for Implementation"; replaces 1999 only when final

Treating a draft guidance as an immediate statutory revocation invites regulatory friction. If an applicant submits an amendment to an in-flight NDA, BLA, or 510(k) stating that it has discontinued compliance with the 1999 guidance because "the 2026 draft repealed it," reviewers can reasonably ask why a non-binding draft was treated as a withdrawal of the still-published 1999 document.

Conversely, regulatory teams cannot simply ignore the draft until it is finalized. In practice, FDA review divisions (particularly CDER OPQ and CDRH Office of Health Technology teams) routinely begin asking questions during pre-submission meetings (Q-Submissions) and formal application reviews that reflect the thinking expressed in published drafts. The compliant operational posture is dual-track:

Maintain the May 1999 baseline as the formal, documented reference in your regulatory dossier.
Benchmark your technical data packages—particularly modern physicochemical characterization, extractables/leachables thresholds, container closure integrity testing (CCIT) deterministic methods, and device-constituent interfaces—against the August 2026 draft to preempt reviewer inquiries.

When Is a Container Closure Also a Device Constituent Part, and When Is It Only Packaging?

The central conceptual expansion in the August 2026 draft—and the reason it directly impacts medical device regulatory professionals—is its explicit integration of combination-product device constituents into the container closure evaluation framework.

Section III.C of the draft addresses this intersection directly. Under FDA regulations (21 CFR 3.2(e)), a combination product includes a product comprised of two or more regulated components (i.e., drug/device, biologic/device, drug/biologic, or drug/device/biologic) that are physically, chemically, or otherwise combined or mixed and produced as a single entity (single-entity combination product), or packaged together in a single package or as a unit (co-packaged combination product). Under 21 CFR 4.2, each individual medical device, drug, or biological product component within the combination is designated a constituent part.

The draft describes a functional test for distinguishing conventional primary packaging from a device-constituent container closure system. Section III.C:

A CCS may also be a device constituent part if it has more than one function (e.g., to be a container closure and to deliver the drug). Examples of CCSs that may also be a device constituent part of a combination product include piston syringes, pumps, metered dose inhalers (MDIs), and intravenous bags.

If a component's sole function is to hold, store, and protect the formulation during storage and transit, it is conventional packaging governed primarily by current good manufacturing practice (CGMP) for finished pharmaceuticals (21 CFR 211.94). As soon as that same physical container participates directly in administering or dispensing the product into or onto the human body, it is treated in this draft as a medical device constituent part.

If the CCS only contains and protects the drug	If the CCS also delivers the drug
Conventional primary packaging (drug/biologic CMC)	Device constituent part under 21 CFR 3.2(e) and Part 4
Examples: glass vial, stopper, blister pack, ampoule	Examples named in Section III.C: piston syringes, pumps, MDIs, intravenous bags
CCS suitability, E&L, and CCIT still apply	CCS suitability tables apply and device CGMP, performance, and human-factors files remain separate

Section III.C names four examples. Adjacent sections add operational color without expanding that list:

Piston syringes. Section V.B.3 uses prefilled syringes as the glide-force / break-force example of a CCS that also delivers.
Pumps. Named in III.C; the draft does not further split mechanical versus electromechanical pumps.
MDIs. Named in III.C; the canister, actuator, and metering valve are described in V.B.3. Dry powder inhalers appear in a separate inhalation-products discussion and in a 2018 MDI/DPI draft footnote — they are not a III.C example.
Intravenous bags. Named in III.C. The draft does not require an "integrated administration port" before the bag counts.
Cartridges labeled for use with a separate device. Not a III.C example. Section V.A.2 notes that testing with a stand-alone device may be needed if a drug cartridge is labeled for use with a reusable pen injector.

The Liquid Medication Dispenser Trap (21 CFR 880.6430)

One of the most consequential warnings in the draft is Footnote 82 to Section V.B.3: quality-system exemptions may not survive incorporation into a container closure.

Under 21 CFR 880.6430, a liquid medication dispenser (a device used to issue a measured amount of liquid medication) is Class I. It is exempt from premarket notification, subject to the limitations in 21 CFR 880.9, and exempt from most QMSR requirements except records and complaint files under 21 CFR 820.35. Footnote 82 restates that ISO 13485:2016 Clauses 4.2.5 and 8.2.2 (records and complaint files) remain among the surviving requirements.

Footnote 82 then warns:

However, if a device that would ordinarily be exempt from all or certain provisions in part 820 is incorporated into a CCS, for example, if a dropper is incorporated into the cap of a bottle of a drug, this may be a new use of the device such that the exemptions from part 820 may not be applicable. In any event, when incorporated into a CCS, the device must be addressed as part of the CCS for purposes of part 211.

Relying on an upstream molder's generic claim that "our dropper is 510(k)-exempt Class I" does not answer that new-use question. The component still needs CCS suitability testing (extractables, leachables, sorption, leak integrity) and, if the exemption does not survive, design and purchasing controls under 21 CFR 820.10.

Does This Draft Apply to Our 510(k), De Novo, PMA, or IDE, or Only to an NDA, ANDA, or BLA?

A second widespread misconception is that because the draft guidance was prepared by CDER Office of Pharmaceutical Quality, it applies exclusively to drug applications (NDAs, ANDAs) and biologics licenses (BLAs).

Section II (Scope) and Footnote 11 explicitly refute this assumption. Footnote 11:

For the purposes of this guidance, the term application refers to investigational new drug applications, new drug applications, abbreviated new drug applications, and biologics license applications. It also includes investigational device exemption applications, premarket approval applications, De Novo requests, and premarket notifications (as described in sections 515, 513(f)(2), and 510(k) of the Federal Food, Drug, and Cosmetic Act ...) for combination products covered by this guidance.

That sentence is vital for medical device regulatory professionals. The mechanism still depends on Primary Mode of Action (PMOA) assignment under 21 CFR Part 3. Footnote 9 adds that combination products whose device constituent is the CCS for a drug or biologic are typically assigned to CDER or CBER, while a drug or biologic constituent may also sit in a CDRH-led combination product.

Lead center (PMOA)	Application type	How the August 2026 CCS draft applies
CDER-led combination (e.g., GLP-1 PFS or autoinjector)	NDA 505(b)(1) or (b)(2), ANDA 505(j)	In scope: CCS data in the quality module; CDRH consults on device performance / EDDO
CBER-led combination (e.g., mAb autoinjector)	BLA 351(a) or 351(k), or IND	In scope: CCS data in the quality module; CDRH consults on device performance / EDDO
CDRH-led combination that holds a drug constituent	510(k), De Novo, PMA, or IDE	In scope if the combination product is covered by this guidance: CCS compatibility, stability, and integrity data in the device filing; CDER/CBER consults on drug/CCS CMC
Stand-alone delivery device (empty general-use syringe, general infusion pump)	510(k), De Novo, or PMA	Excluded from stated scope; sponsor may discuss applicable principles with CDRH or CBER

For detailed background on how FDA determines center jurisdiction and assigns the lead review division, consult our foundational combination products regulatory framework guide.

How the Draft Operates Across Centers

In a CDER- or CBER-Led Submission (NDA, BLA): The drug or biologic sponsor files an electronic Common Technical Document (eCTD). Draft Table 4 maps CCS information for the drug product to eCTD 2.3.P.7 / 3.2.P.7 (description, suitability, and related reports). ICH M4Q still commonly also places container-closure development discussion in 3.2.P.2.4; treat that as CTD structure, not as a second legal requirement invented by this article. Footnote 91 points device-constituent formatting to FDA's eCTD technical specifications rather than rewriting eSTAR here. CDRH participates through an inter-center consult. CDRH reviewers evaluate mechanical, electrical, software, and human-factors performance of the device constituent, while CDER/CBER OPQ reviewers evaluate chemical suitability, safety, and microbiological integrity of the CCS.
In a CDRH-Led Submission (510(k), De Novo, PMA): Where the combination product is covered by this guidance and the device application holds a drug constituent, the applicant still needs evidence that the CCS does not adversely alter the safety, identity, strength, quality, or purity of the drug. CDER or CBER reviewers may be consulted against the same CCS principles. The draft is not a substitute for the device-performance file.
In Investigational Settings (IND or IDE): Section VI.B and Footnote 92 treat investigational applications as INDs and as IDEs for device-led combination products. For IDEs, 21 CFR 812.27 still governs nonclinical testing content. The draft says the type and extent of CCS testing for the drug are generally the same for IDEs and INDs, and that the amount of CMC detail depends on phase, study nature, and whether the information is safety-related. It does not require sponsors to "directly reference" this draft's risk tables as a clinical-start condition.

What Remains Beyond Scope: Stand-Alone Devices, Packaging Operations, Child-Resistant Packaging, Part 4, Human Factors, and EDDO?

To prevent scope creep, Section II and Section V.B.3 draw explicit boundaries. Regulatory teams need to know what the draft does not cover:

In scope of the August 2026 CCS draft	Beyond the scope of this CMC file (governed elsewhere)
Primary packaging components and closures	Stand-alone delivery devices (discuss with CDRH or CBER)
Secondary packaging if its purpose is to further protect the drug (draft lines 71–73)	Packaging operations (filling, packaging, labeling)
Extractables and leachables, CCIT, sorption, compatibility, stability, barrier	Child-resistant packaging (PPPA / 16 CFR Part 1700)
Device-constituent CCS that contains and delivers	21 CFR Part 4 CGMP and postmarketing safety reporting
Type II/III DMF content described in Section VI.C; device master-file URL in footnote 94	Premarket device-performance, human-factors, and EDDO files
	ISO 11608 mechanical verification (not this CMC draft)

1. Stand-Alone Medical Devices

Lines 46–49:

Although the scope of this guidance excludes stand-alone devices, and its focus is on CCSs that package drugs or biological products, some recommendations described in this guidance also may be applicable to stand-alone devices intended to deliver drugs.

Footnote 10: questions about a specific device should be discussed with the CDRH or CBER review division during development. An empty, general-use syringe cleared under a 510(k) without a pre-filled or co-packaged drug is not automatically in scope.

2. Packaging Operations and Child-Resistant Packaging

These are two separate exclusions, not one combined sentence:

Lines 57–58: "This guidance is not intended to address packaging operations (e.g., processes of filling, packaging, and labeling) associated with drug product manufacture."
Lines 60–66: the draft does not cover child-resistant packaging standards. PPPA / 16 CFR Part 1700 remain the CPSC rules. For labeling statements, the applicant should follow FDA's August 2019 guidance Child-Resistant Packaging Statements in Drug Product Labeling, including written verification that the packaging meets 16 CFR Part 1700.

3. The Decisive Device-RA Boundary: Section V.B.3

The heading on page 25 is Packaging Components for Device Constituent Parts of Combination Products. Lines 821–826:

A CCS that is also a device constituent part of a combination product is subject to certain regulatory requirements that are beyond the scope of this guidance. These requirements include, but are not limited to, CGMP and postmarketing safety reporting requirements under 21 CFR part 4 and the submission of information in premarket applications to support the safety and effectiveness of the combination product, including the performance of the device constituent part.

That paragraph refutes the claim that the draft brings all combination-product device rules "under one roof." The CCS quality file does not replace the device constituent file:

21 CFR Part 4: After the QMSR effective date of 2 February 2026, the streamlined approach in 21 CFR 4.4(b)(1) (drug CGMP as the base) requires showing ISO 13485:2016 Clause 4.1, Clause 5, Clause 6.1 and 21 CFR 820.10; Clause 7.3 (design and development) plus documented risk management; Clause 7.4 (purchasing); Clause 8.2.2 / 21 CFR 820.35(a), Clause 8.4, and Clause 8.5 (analysis, improvement, complaint handling); and, where applicable, Clause 7.5.3 (installation) and Clause 7.5.4 / 21 CFR 820.35(b) (servicing). Those are the current Part 4 device add-ons — not the pre-QMSR 820.20 / 820.30 / 820.50 section numbers. Review the 21 CFR Part 4 compliance guide for dual versus streamlined execution.
QMSR overlap (21 CFR 820.10): Footnote 24 cites 89 FR 7496, effective 2 February 2026. Section V.B.3 says Clause 7.3 as required by 21 CFR 820.10(c), and Clause 7.4 as required by 21 CFR 820.10(a) for supplied components, may overlap CCS quality assessments. Glide-force and break-force tests in V.B.3 are CCS performance examples; they do not retire the rest of the design-control file.
Human factors: V.B.3 says other assessments "may include human factors studies to evaluate the user interface." Footnote 86 cites FDA's September 2023 combination-product human-factors Q&A (and an ANDA comparative-use draft), not the 2026 device HF final as this CMC draft's legal text. Keep a separate HF file; see FDA human factors submission categories and Decision Point D and autoinjector critical-task matrices.
Essential Drug Delivery Outputs (EDDO): Footnote 83 cites the June 2024 EDDO draft (when final, FDA's current thinking). CCS integrity and delivery-volume tests in this CMC draft do not replace that performance file. See on-body delivery systems and EDDO and GLP-1 delivery platforms.
Mechanical standards: ISO 11608 remains applicable to needle-based injection systems; it is not this CMC draft. See the ISO 11608 design verification framework.

What Fails If You Treat a Law-Firm Alert as the Legal Text, Merge the Biosimilar Twin Docket, or Count Public 510(k) Rows as CCS Combination Products?

Operating on secondary commentary, misattributed dockets, or a public 510(k) export as if it were a combination-product census creates four practical failure modes:

Failure mode	What goes wrong
Treating a draft as already superseding 1999	Dropping the still-published 1999 CCS file from an in-flight NDA, BLA, DMF, or 510(k)
Treating CCS CMC as "device rules under one roof"	Omitting ISO 13485 design controls, human factors, or EDDO because "CCS now covers devices"
Merging the two summer-2026 dockets	Filing comments or citations on FDA-2026-D-4272 as if it were FDA-2026-D-7957
Counting 175,559 public 510(k) rows as CCS combination products	Using a snapshot with no combination-product or CCS field as a clearance census

Failure Mode 1: Asserting in Formal Submissions That the 1999 Guidance Is Superseded

Some secondary alerts, including an August 25, 2026 law-firm post, write that the draft "supersedes" the 1999 guidance. That is not what lines 22–24 of the PDF say. Relying on the secondary phrasing can lead teams to delete 1999 references from annual reports, Type II/III DMFs, or 3.2.P.7 modules. The operating file is still the published 1999 listing plus a non-binding 2026 draft stamped "Not for Implementation."

Failure Mode 2: Treating CCS CMC as a One-Roof Device File

The same class of commentary also describes the draft as placing combination-product threads "under one roof." Section V.B.3 says the opposite for Part 4 CGMP, postmarketing safety reporting, and device-performance information. Missing design controls, human-factors evidence, or EDDO is a Part 4 / premarket-completeness problem — not an automatic Refuse-to-Accept action "under 21 CFR Part 4." RTA is a 510(k) administrative completeness check; CDER/CBER deficiency letters are a different instrument. Do not collapse those clocks.

Failure Mode 3: Conflating the General CCS Docket with the Biosimilar Twin Docket

In summer 2026, FDA issued two distinct, highly consequential draft guidances regarding container closure systems and device constituent parts:

Dimension	General Container Closure Draft (This Guidance)	Biosimilar Container Closure Draft (Companion Guidance)
Full Title	Container Closure Systems for Human Drugs and Biological Products	Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts
Docket Number	Docket No. FDA-2026-D-7957	Docket No. FDA-2026-D-4272
Federal Register	91 FR 52700 (August 14, 2026)	91 FR 48880 (August 3, 2026)
Comment Deadline	October 13, 2026	October 2, 2026
Target Audience	All NDAs, ANDAs, BLAs, 510(k)s, PMAs, and DMF holders	351(k) BLA biosimilar and interchangeable biosimilar sponsors
Core Regulatory Focus	Materials, extractables/leachables, CCIT, compatibility, secondary barrier, device-constituent function	Comparative design, presentation differences (e.g., vial vs. autoinjector), human factors threshold studies

Conflating these two documents compromises your public comment strategy and misaligns regulatory dossiers. If a sponsor filing a standard 505(b)(2) NDA or device 510(k) cites the biosimilar docket's rules on presentation differences, the citation will be rejected as inapplicable.

Failure Mode 4: Treating the Public FDA 510(k) Export as a Combination-Product CCS Census

The July 22, 2026 public FDA 510(k) export (175,559 premarket-notification records in the committed snapshot used for this article) is a completeness check of that device-clearance feed, not a combination-product CCS inventory. The public descriptor for that extract lists keywords for FDA 510(k), premarket notification, medical devices, and substantial equivalence. It does not publish a combination-product, container, or closure field that would support a CCS headcount.

Filtering stand-alone product codes — for example piston-syringe codes — cannot create that missing field. Many cleared syringes are stand-alone devices outside this draft's stated scope, while many combination-product CCS files live in CDER or CBER applications with CDRH consults and never appear as a 510(k) row. Do not present 175,559 as the number of combination-product CCS devices. The official public source is FDA's 510(k) Premarket Notification database.

FDA CCS Draft 30/60/90-Day SKU Map: Comment by 13 October 2026, Keep 1999, Gap-Assess Device-Constituent Overlap

To operationalize the August 2026 draft across a portfolio of prefilled syringes, autoinjectors, pumps, and other dual-function CCS, use a 30/60/90-day map timed to the comment window — not to an application expiry:

Window	Job	Not this job
Days 1–30	Inventory dual-function CCS SKUs; audit Type III DMF and CDRH MAF coverage; file comments on Docket FDA-2026-D-7957 by October 13, 2026 if you want them considered before work on the final starts	Treat October 13 as a marketing-application clock
Days 31–60	Gap-assess CCIT, E&L, and ISO 13485 Clause 7.3 / 7.4 overlap against the 1999 file plus the 2026 draft	Replace 1999 with the draft in the dossier
Days 61–90	Update supplier change-notification agreements; align eSTAR / Module 3 playbooks; re-check 21 CFR 880.6430 dropper-in-cap uses	Merge Docket FDA-2026-D-4272 into the same comment or citation

Days 1–30: Immediate Portfolio Triage and Comment Submission

Audit Dual-Function Packaging: Categorize every container closure in your commercial and clinical pipeline. Identify which components only hold product (vials, stoppers, ampoules) and which perform a dual contain-and-deliver function (PFS, autoinjector cartridges, MDIs, elastomeric pumps).
Review Master File Authorizations: Check whether primary component suppliers (glass syringe molders, elastomeric stopper manufacturers, valve fabricators) hold active Type III Drug Master Files (CDER) or Medical Device Master Files (CDRH MAF). For detailed guidance on master file structure and Letters of Authorization (LOAs), consult our FDA Medical Device Master File (MAF) guide.
Execute Comment Strategy Before October 13, 2026: Review specific pain points in the draft:
- Extractables/Leachables Thresholds: Evaluate whether the draft's expectations for safety assessment align with your analytical capabilities, noting that ICH Q3E remains under development.
- Postconsumer recycled plastic: Lines 528–531 say postconsumer recycled plastic should not be used in the manufacture of a primary packaging component. If it is used for a secondary packaging component, safety and compatibility for the intended use should be addressed. That is a draft recommendation, not a statute or a ban. If you are advancing recycled-polymer primary packaging, that is a comment topic for Docket FDA-2026-D-7957.
- Comment logistics: File via Regulations.gov under Docket No. FDA-2026-D-7957. The Federal Register notice asks for comments by October 13, 2026 to ensure that the Agency considers your comment before it begins work on the final version. 21 CFR 10.115(g)(5) still allows comments on any guidance at any time.

Days 31–60: Technical and Methodological Gap Assessment

Container Closure Integrity Testing (CCIT): Compare your legacy dye-ingress and microbial challenge testing against modern deterministic CCIT methods referenced in USP <1207> and the draft (e.g., high-voltage leak detection, vacuum decay, laser-based headspace analysis).
QMSR Clause 7.3 Design Controls Alignment: Ensure that mechanical testing of the CCS (glide force, pull-off force, burst pressure, dose accuracy) is documented within design verification protocols that satisfy ISO 13485:2016 Clause 7.3, as incorporated by 21 CFR 820.10.
Review 21 CFR Part 4 Streamlined Operating Procedures: Verify that change-control SOPs require an assessment of both drug stability and device mechanical function whenever an elastomeric formulation or silicone oil coating level is modified.

Days 61–90: Supplier Agreements and Dossier Readiness

Update Supplier Quality Agreements (ISO 13485 Clause 7.4): Bind component molders to documented change-notification windows for resin, mold, or process-aid changes. The draft does not prescribe a 90- or 180-day legal clock; those windows are contractual.
eSTAR and Module 3 Submission Playbooks: In upcoming 510(k) submissions utilizing FDA's electronic Submission Template And Resource (eSTAR), ensure device-constituent container closures clearly cross-reference biocompatibility, chemical characterization, and physical delivery outputs without misrepresenting the draft as a finalized standard.
Audit Closure Accessories: Review whether any calibrated dosing droppers or cups are physically incorporated into primary caps, ensuring that Class I 510(k) exemptions under 21 CFR 880.6430 are not being improperly claimed for combination container closures.

What Does This Cost: Commenting Is Free Versus DMF/MAF File Control and Ordinary Application User Fees?

Budgeting against this draft means separating $0 FDA comment and master-file filing fees from ordinary application user fees and from laboratory/provider costs that FDA does not schedule.

Cost category	Official FDA / statutory fee	What is not an official fee	Source basis
Docket FDA-2026-D-7957 comment	$0	Internal legal, RA, and CMC time to draft comments	21 CFR 10.115; Regulations.gov; 91 FR 52700
CDRH Medical Device Master File (MAF)	$0 MDUFA fee to establish an MAF or issue an LOA	Holder compilation and annual maintenance (provider or internal cost)	CDRH MAF program; see MAF vs DMF
CDER Type III packaging DMF	$0 PDUFA/GDUFA fee for a Type III packaging DMF	Supplier technical documentation	GDUFA DMF fees apply to Type II API DMFs, not Type III packaging files
CCIT, E&L, and ISO 11608 laboratory work	$0 FDA test tariff	Contract-lab or in-house characterization; amounts vary by SKU, method, and provider and are not published by FDA	USP 1207, USP 1663/1664, ISO 10993-18, ISO 11608 — provider invoices, not an FDA schedule
510(k) user fee	FY 2026 (through Sep 30, 2026): $26,067 standard / $6,517 small business. FY 2027 (from Oct 1, 2026): $28,653 / $7,163	Consulting, testing, and dossier labor	Medical Device User Fee Rates for FY 2026 (90 FR 35895); FY 2027 MDUFA table (91 FR 48134)
PMA user fee	FY 2026: $579,272 standard / $144,818 small business. FY 2027: $636,732 / $159,183	Clinical and total-project cost	Same MDUFA notices
NDA / BLA application fee (clinical data)	FY 2026 PDUFA: $4,682,003. FY 2027 PDUFA (from Oct 1, 2026): $4,600,753	Dossier compilation	Prescription Drug User Fee Rates for FY 2026; FY 2027 notice 2026-15334

FY 2026 device and drug user fees remain in effect through September 30, 2026. A combination-product filing on or after October 1, 2026 uses the FY 2027 row. Small-business MDUFA rates require a current-year Small Business Determination. Commenting on this CCS docket does not create a CCS-specific FDA tariff. For 510(k) mechanics see the FY 2026 MDUFA V schedule.

Frequently Asked Questions (FAQ)

Does the August 2026 draft already supersede the May 1999 container-closure guidance?

No. The August 2026 document is a draft guidance marked "Draft — Not for Implementation." It is non-binding under 21 CFR 10.115. Lines 22–24 of the draft state that it will supersede the May 1999 guidance Container Closure Systems for Packaging Human Drugs and Biologics and the May 2002 Q&A when final. Until a final guidance is published, the May 1999 document remains active and indexed on FDA's website. Keep the 1999 file as the still-published CCS guidance and use the 2026 draft to anticipate reviewer questions and structure comments.

If our autoinjector is cleared in a 510(k) as part of a combination product, does this CMC draft apply?

Yes, if the combination product is covered by this guidance. Footnote 11 — not a CDER-only reading of Section II — includes 510(k)s, De Novo requests, PMAs, and IDEs in "application" for those combination products. If the device constituent contains and delivers the drug (for example an autoinjector holding a prefilled syringe or cartridge), the chemical suitability, barrier, and E&L recommendations in this draft are in play. In a CDRH-led file, CDER or CBER quality reviewers may still be consulted. The CCS tables do not replace the device-performance file.

Is this the same document as FDA's biosimilar CCS and device-constituent draft?

No. These are two distinct draft guidances published under separate dockets with different comment deadlines:

This Guidance: Container Closure Systems for Human Drugs and Biological Products (Docket No. FDA-2026-D-7957, published August 14, 2026, at 91 FR 52700; comments due October 13, 2026). It addresses universal CMC quality, materials, CCIT, and device-constituent functions.
Biosimilar Guidance: Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts (Docket No. FDA-2026-D-4272, published August 3, 2026, at 91 FR 48880; comments due October 2, 2026). It focuses on comparative design, presentation differences, and user-interface threshold evaluations for 351(k) biosimilar applications.

Do we still need a separate Part 4, human-factors, and essential-drug-delivery-output file?

Yes. Section V.B.3 explicitly establishes that a CCS that is also a device constituent part remains subject to 21 CFR Part 4 CGMP (including ISO 13485:2016 design controls and purchasing controls under QMSR), postmarketing safety reporting (PMSR), device performance testing, and human factors data that are beyond the scope of this CMC guidance. Technical data regarding container closure suitability cannot replace your Design History File, usability validation under FDA's human factors guidance, or Essential Drug Delivery Output (EDDO) verification across product shelf-life.

If a dropper was quality-system exempt as a liquid medication dispenser, does building it into a bottle cap change that?

Yes, it may. 21 CFR 880.6430 classifies a liquid medication dispenser as Class I, 510(k)-exempt subject to 21 CFR 880.9, and QMSR-exempt except for records and complaint files under 21 CFR 820.35. Footnote 82 warns that if an otherwise exempt dropper is incorporated into the cap of a drug bottle, that may be a new use so the part 820 exemptions may not apply — and the dropper must still be addressed as part of the CCS under part 211.

Is there an FDA user fee to comment on Docket FDA-2026-D-7957?

No. FDA does not charge a user fee to comment. File via Regulations.gov under Docket No. FDA-2026-D-7957. Comments by October 13, 2026 are requested so FDA can consider them before work on the final version begins. 21 CFR 10.115(g)(5) still allows comments later.

How Pure Global Supports FDA Combination Product and Device-Constituent Strategy

Aligning container closure CMC data with medical device design controls, human factors validation, and CDRH/CDER inter-center reviews requires deep, cross-functional regulatory engineering. Pure Global provides comprehensive regulatory strategy, technical documentation, and market-access support for medical device, pharmaceutical, and combination-product manufacturers.

Pure Global's multidisciplinary practice supports teams by:

Structuring integrated US regulatory dossiers for United States market access, aligning CDER/CBER Module 3 container closure sections with CDRH device-constituent eSTAR filings.
Auditing existing combination product quality systems against 21 CFR Part 4, ISO 13485:2016 Clauses 7.3 and 7.4, and the QMSR final rule.
Navigating global drug-device interfaces, including EU MDR consulting for Article 117 Notified Body Opinions (NBOp) and Annex I General Safety and Performance Requirements (GSPR) documentation.
Formulating technical docket comments and pre-submission strategies (Q-Submissions) to resolve extractables/leachables thresholds, deterministic CCIT protocols, and essential drug delivery output boundaries.
Auditing component supplier master files (Type III DMFs and CDRH MAFs) to secure robust Letters of Authorization without intellectual property exposure.

To evaluate your container closure systems, prefilled syringes, or autoinjector platforms against emerging FDA expectations, contact Pure Global.

Disclaimer: Pure Global provides professional regulatory and compliance consulting. Pure Global is not the U.S. FDA, a Notified Body, or a government competent authority, and does not issue statutory marketing authorizations or clearance orders.

Sources

Container Closure Systems for Human Drugs and Biological Products — Draft Guidance for Industry (PDF) — U.S. Food and Drug Administration (CDER, CBER, CDRH, ORA/OII, OCP), August 2026.
Container Closure Systems for Human Drugs and Biological Products; Draft Guidance for Industry; Availability (91 FR 52700) — Federal Register Notice, Docket No. FDA-2026-D-7957, August 14, 2026.
Container Closure Systems for Packaging Human Drugs and Biologics — Guidance for Industry (May 1999 Listing) — U.S. Food and Drug Administration, Content current as of May 6, 2020.
21 CFR Part 3 — Product Jurisdiction and Combination Products — Electronic Code of Federal Regulations, Sections 3.2(e) and 3.4.
21 CFR Part 4 — Regulation of Combination Products — Subpart A (CGMP Requirements) and Subpart B (Postmarketing Safety Reporting).
Medical Devices; Quality System Regulation Amendments (QMSR Final Rule; 89 FR 7496) — Federal Register Notice incorporating ISO 13485:2016 into 21 CFR Part 820, effective February 2, 2026.
21 CFR 880.6430 — Liquid Medication Dispenser — Classification and limitations of exemptions under 21 CFR 880.9.
Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts (July 2026 Draft) — U.S. Food and Drug Administration, Docket No. FDA-2026-D-4272, 91 FR 48880.
Principles of Premarket Pathways for Combination Products (January 2022) — Guidance for Industry, U.S. Food and Drug Administration.
Essential Drug Delivery Outputs for Devices and Device Constituent Parts of Combination Products (June 2024 Draft) — Guidance for Industry, U.S. Food and Drug Administration.
FDA Premarket Notification 510(k) Database — U.S. Food and Drug Administration CDRH public 510(k) search. The 175,559-row figure is the July 22, 2026 public export used for a schema check, not a combination-product CCS census.
Medical Device User Fee Rates for Fiscal Year 2026 (90 FR 35895) — FY 2026 510(k) $26,067 / $6,517; PMA $579,272 / $144,818, through September 30, 2026.
Prescription Drug User Fee Rates for Fiscal Year 2026 — FY 2026 PDUFA application fee requiring clinical data $4,682,003.
21 CFR 4.4 — Streamlined combination-product CGMP after QMSR — ISO 13485:2016 clauses incorporated for the drug-CGMP-base pathway; eCFR current as of September 3, 2026.